Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 1/20 | 0.54 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.46 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.44 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL597775 | 1.00 | CTSD (0.54) | CTSDDDB1CRBNKCNA5CYP26A1 | |
| SCHEMBL597776 | 1.00 | CTSD (0.54) | CTSDDDB1CRBNKCNA5CYP26A1 | |
| SCHEMBL19419777 | 0.90 | CTSD (0.59) | CTSDDDB1CRBNKCNA5POLB | |
| SCHEMBL8270781 | 0.90 | CTSD (0.59) | CTSDDDB1CRBNKCNA5POLB | |
| SCHEMBL2132646 | 0.90 | CTSD (0.59) | CTSDDDB1CRBNKCNA5POLB | |
| Tert-Butyl Formate SCHEMBL28003304 | 0.86 | CTSD (0.47) | CTSDDDB1CRBNKCNA5CYP26A1 | |
| Tert-Butyl Formate SCHEMBL28003305 | 0.86 | CTSD (0.47) | CTSDDDB1CRBNKCNA5CYP26A1 | |
| SCHEMBL14932461 | 0.84 | KCNA5 (0.49) | CTSDKCNA5CD274 | |
| SCHEMBL18409007 | 0.84 | KCNA5 (0.43) | CTSDKCNA5CD274 | |
| SCHEMBL23459341 | 0.82 | CTSD (0.58) | CTSDDDB1CRBNPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117285442-A | Preparation method of sakuba intermediate LCZ696 intermediate | 安徽迪合永欣药业有限公司 | 2023-12-26 | — | — | CN | claimed |
| CN-115974725-A | Method for preparing pharmaceutical intermediate | 深圳市祥根生物医药有限公司 | 2023-04-18 | — | — | CN | claimed |
| CN-117285442-A | Preparation method of sakuba intermediate LCZ696 intermediate | 安徽迪合永欣药业有限公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-117285442-A | Preparation method of sakuba intermediate LCZ696 intermediate | 安徽迪合永欣药业有限公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-115974725-A | Method for preparing pharmaceutical intermediate | 深圳市祥根生物医药有限公司 | 2023-04-18 | — | — | CN | disclosed |
| CN-115974725-A | Method for preparing pharmaceutical intermediate | 深圳市祥根生物医药有限公司 | 2023-04-18 | — | — | CN | disclosed |
| EP-2121578-B1 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | NOVARTIS AG (CH) | 2016-08-10 | — | — | EP | disclosed |
| US-9206116-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2015-12-08 | — | — | US | disclosed |
| US-20150166468-A1 | Process for Preparing 5-biphenyl-4-amino-2-methyl Pentanoic Acid | NOVARTIS AG (CH) | 2015-06-18 | — | — | US | disclosed |
| US-8993785-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2015-03-31 | — | — | US | disclosed |
| CN-101631765-B | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2014-10-01 | — | — | CN | disclosed |
| US-20140249320-A1 | Process for Preparing 5-biphenyl-4-amino-2-methyl Pentanoic Acid | NOVARTIS AG (CH) | 2014-09-04 | — | — | US | disclosed |
| US-8716495-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2014-05-06 | — | — | US | disclosed |
| US-20120142916-A1 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | disclosed |
| US-8115016-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2012-02-14 | — | — | US | disclosed |
| US-20100113801-A1 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-05-06 | — | — | US | disclosed |
| EP-2121578-A2 | NEW PROCESS | Novartis AG (CH) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008083967-A2 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | NOVARTIS AG (CH) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113801-A1 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | MME, REN, PAH | CTSD 2264/4885DDB1 3871/4885CRBN 1031/4885 |
| US-20120142916-A1 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | MME, REN, PAH | CTSD 2264/4885DDB1 3871/4885CRBN 1031/4885 |
| US-20140249320-A1 | Process for Preparing 5-biphenyl-4-amino-2-methyl Pentanoic Acid | MME, REN, PAH | CTSD 2264/4885DDB1 3871/4885CRBN 1031/4885 |
| US-20150166468-A1 | Process for Preparing 5-biphenyl-4-amino-2-methyl Pentanoic Acid | MME, REN, PAH | CTSD 2264/4885DDB1 3871/4885CRBN 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.